N-(2'-pyridyl)-2-chloro-1-methylindole-3-carboxamide | 156136-94-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(2'-pyridyl)-2-chloro-1-methylindole-3-carboxamide
• 英文别名: 2-chloro-1-methyl-N-pyridin-2-ylindole-3-carboxamide
• CAS: 156136-94-6
• 化学式: C₁₅H₁₂ClN₃O
• 分子量: 285.733
• InChiKey: GDWRAFUEHSGTEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2'-pyridyl)-2-chloro-1-methylindole-3-carboxamide 在 lithium methanethiolate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 7.0h， 生成 1-Methyl-2-thioxo-2,3-dihydro-1H-indole-3-carboxylic acid pyridin-2-ylamide
  参考文献：
  名称：

  Tyrosine Kinase Inhibitors. 4. Structure-Activity Relationships among N- and 3-Substituted 2,2'-Dithiobis(1H-indoles) for in vitro Inhibition of Receptor and Nonreceptor Protein Tyrosine Kinases

  摘要：

  A series of S-substituted 2,2'-dithiobis(1H-indoles) were synthesized and evaluated for their ability to inhibit the tyrosine kinase activity of both the epidermal growth factor receptor (EGFR) and the nonreceptor pp60(v-src) tyrosine kinase, to extend the available structure-activity relationships for this series. The majority of the compounds were prepared either by reaction of 2-chloro-1-methylindole-3-carbonyl chloride with amines, followed by thiomethylation, demethylation, and oxidative dimerization, or by reaction of isocyanates with the anion of 1-methyl-2-indolinethione followed by dimerization. Overall, inhibitory activity is retained by analogues having a wide variety of side chains. A series of 3-carboxamide analogues had moderate to good activity against isolated EGFR (IC(50)s 1-20 mu M), with monoalkyl substitution of the carboxamide being optimal. Polar side chains were generally less effective than lipophilic ones, with benzyl being particularly effective. However, N,N-disubstitution was the most effective pattern for inhibition of pp60(v-src). A variety of substituted N-phenylcarboxamides had lower activity against EGFR than the parent derivative, and a N-thienylcarboxamide also had low activity. A series of 3-ketones, including methyl, phenyl, and furyl derivatives, showed moderate activity against the pp60(v-src) kinase, but were less effective against EGFR. The mechanism of inhibition of both kinases by these drugs was shown to be noncompetitive with respect to both ATP and peptide substrate. Selected compounds inhibited the growth of Swiss 3T3 cells with IC(50)s in the low micromolar range and inhibited bFGF-mediated intracellular tyrosine phosphorylation in the same cell line. Thiol inhibits the effects of the compounds, suggesting that one possible mechanism of inhibition is thiol-disulfide exchange with thiol-containing residues in the catalytic sites. Crystal structures of two representative compounds show a folded, V-shaped structure, with the disulfide bridge exposed, consistent with this hypothesis.

  DOI：

  10.1021/jm00001a011
• 作为产物：
  描述：

  2-氨基吡啶 、 2-氯-N-甲基-3-吲哚醛肟 在 氯化亚砜 作用下， 以42%的产率得到N-(2'-pyridyl)-2-chloro-1-methylindole-3-carboxamide
  参考文献：
  名称：

  2-thioindoles (selenoindoles) and related disulfides (selenides) which

  摘要：

  本文揭示了2-硫代吲哚（2-硒代吲哚）及类似的2-吲哚硫酮（2-吲哚硒酮）和聚硫化物（硒化物）化合物，以及其盐、生产方法、生产中间体、含有该类化合物的药物组合物，以及使用这些组合物来抑制蛋白激酶依赖性疾病或治疗哺乳动物中的异常细胞生长的方法。

  公开号：

  US05464861A1

文献信息

• N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
  申请人：NOVO NORDISK A/S

  公开号：EP1532980A1

  公开（公告）日：2005-05-25

  This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is benefical, such as diabetes. The compounds are of the general formula (I) wherein B is and A is heteroaryl as defined in the claims.

  本发明涉及一种激活葡萄糖激酶的化合物，因此可能有助于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病，例如糖尿病。化合物的一般式（I）中，B为，A为异杂环，如权利要求所定义。
• N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes
  申请人：Lau F. Jesper

  公开号：US20070027140A1

  公开（公告）日：2007-02-01

  This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherin A and B are further defined in the application.

  本发明涉及激活葡萄糖激酶的化合物，因此可能对增加葡萄糖激酶活性有益的疾病的管理、治疗、控制或辅助治疗具有用处。这些化合物的一般式为（I）其中A和B在申请中有进一步定义。
• N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES
  申请人：Lau Jesper F.

  公开号：US20110082144A1

  公开（公告）日：2011-04-07

  This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.

  本发明涉及一种激活葡萄糖激酶的化合物，因此可能有助于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。该化合物的一般公式为(I)，其中A和B在申请中有进一步定义。
• 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0654024A1

  公开（公告）日：1995-05-24
• US5464861A
  申请人：——

  公开号：US5464861A

  公开（公告）日：1995-11-07